| Description |
1 online resource (298 p.) |
| Series |
Perspectives in Translational Cell Biology Ser |
|
Perspectives in Translational Cell Biology Ser
|
| Contents |
Front Cover -- MECHANISMS OF CELL DEATH AND OPPORTUNITIES FOR THERAPEUTIC DEVELOPMENT -- MECHANISMS OF CELL DEATH AND OPPORTUNITIES FOR THERAPEUTIC DEVELOPMENT -- Copyright -- Contents -- List of contributors -- 1 -- Apoptosis, necroptosis, and pyroptosis in health and disease: an overview of molecular mechanisms, targets for ... -- 1. Introduction -- 2. The apoptotic pathways and major targets for drug development -- 2.1 An overview of the molecular mechanism of apoptosis -- 2.2 BCL-2 family proteins -- 2.3 Inhibitor of apoptosis proteins (IAPs) -- 2.4 PARAs -- 2.5 Other targets of the apoptosis pathways -- 3. Necroptosis: mechanism, disease implications, and potential therapeutics -- 3.1 Mechanism of necroptosis -- 3.2 Necroptosis in diseases -- 3.3 Necroptosis-targeting agents -- 3.4 Agents that indirectly affect necroptosis -- 4. Pyroptosis -- 4.1 NLRP1 inflammasomes -- 4.2 NLRP3 inflammasomes -- 4.3 NLRC4 inflammasomes -- 4.4 Noncanonical inflammasomes -- 4.5 Noncanonical pyroptotic pathway -- 4.6 Inflammasome dysregulation in diseases -- 4.7 Targeting inflammasome for treating diseases -- 5. Concluding remarks -- References -- 2 -- Cell death: machinery and regulation -- 1. Introduction -- 2. Nonapoptotic cell death -- 2.1 Necroptosis -- 2.2 Pyroptosis -- 2.3 Ferroptosis -- 2.4 Other -- 3. Apoptotic cell death -- 3.1 Apoptotic pathways -- 3.2 Apoptotic regulators -- 3.2.1 Caspase family -- 3.2.2 BCL2 family -- 3.2.3 IAP family -- 3.2.4 HSP family -- 4. Conclusions and perspectives -- Acknowledgments -- References -- 3 -- Molecular mechanisms of cell death: a brief overview -- 1. Introduction -- 2. Intrinsic apoptotic pathway -- 3. Extrinsic apoptotic pathway -- 4. Caspases -- 5. The inhibitors of apoptosis -- 6. Other types of programmed cell death -- 6.1 Necroptosis (programmed necrosis) -- 6.2 Ferroptosis -- 6.3 Pyroptosis -- 7. Conclusion |
|
4.4 Cardiac disease -- 4.5 Diabetes and obesity -- 4.6 Muscle atrophy -- 4.7 Cancer -- 5. Disease intervention for ER stress-related disorders -- 5.1 Neuroprotective drugs -- 5.1.1 ER chaperone modulators -- 5.1.2 Autophagy inducers -- 5.1.3 Others -- 5.2 Treatments for cardiac diseases -- 5.2.1 Chemical ER chaperones -- 5.2.2 Agents inhibiting CHOP -- 5.2.3 Others -- 5.3 Diabetes and obesity therapeutics -- 5.3.1 Drugs that mildly activate UPR -- 5.4 Cancer therapeutics -- 5.4.1 GRP78 inhibitors -- 5.4.2 Proteasome inhibitors -- 5.4.3 Others -- 5.4.4 Future directions -- 5.4.5 Selecting therapeutic modes of ER stress initiation and control of the off-target effects of ER stress induction -- 5.4.6 Potential resistance mechanisms to proteotoxic therapy -- 5.4.7 Programming cell type-specific induction of ER stress -- References -- 6 -- Protein phase separation in cell death and survival -- 1. Phase separation -- 1.1 Biological relevance -- 1.2 Hallmarks of phase separation -- 1.3 Testing phase separation -- 2. Cell death pathways -- 2.1 Apoptosis -- 2.1.1 DAXX -- 2.1.2 YAP -- 2.1.3 cGAS-STING -- 2.2 Autophagic death and aggregates -- 2.2.1 Aggregates and PTMs -- 2.2.2 Autophagic death -- 3. Cell survival: cancer and the avoidance of cell death -- 3.1 Autophagy and cancer -- 3.2 Cancer and phase separation -- 4. Conclusion -- References -- 7 -- Therapeutics targeting BCL2 family proteins -- 1. Apoptotic pathways -- 1.1 Apoptosis definition and function -- 1.2 Two different apoptotic pathways -- 1.3 Downstream of the mitochondrial apoptotic pathway -- 2. Structure and function of BCL2 family proteins -- 2.1 The discovery of BCL2 family proteins -- 2.2 Structures of BCL2 family proteins -- 2.2.1 Structure of antiapoptotic BCL2 family members -- 2.2.2 Structure of pro-apoptotic BAK/BAX -- 2.2.3 Structure of BH3-only proteins |
|
S -- T -- U -- V -- W -- X -- Z -- Back Cover |
| Notes |
Description based upon print version of record |
| Form |
Electronic book
|
| ISBN |
9780128142097 |
|
012814209X |
|
